IL6 and neoplasm: Indeed, IL-6 signalling is pleiotropic and highly complex, and alongside its well-known tumour-promoting effects, it paradoxically promotes effector T cell priming within lymph nodes and subsequent trafficking to tumour sites, which in turn suppresses tumour development (244).